Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
GSK, Amgen want SCOTUS to protect genus claims
18-11-2020
Vectura wins additional $10m patent damages against GSK
16-09-2019
The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s (GSK) challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, GlaxoSmithKline, Vectura, patent infringement, inhalers, Federal Circuit, Ellipta
